ArticleACS omega2026
Concomitant Effect of Left-Wing Disaccharide, Chain Length, and Modification of C23-Aldehyde: An Effort to Develop Simple and Effective QS-21 Derivative Vaccine Adjuvants and Exploration of the Structural-Activity Relationship.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adjuvants are the substances added to a vaccine for eliciting and modulating immune response. QS-21 is the most promising candidate that is employed in certain adjuvant formulations, e.g., AS01, but due to its inherent toxicity, there is a need to develop vaccine adjuvant candidates that are less toxic and more potent. The importance of the saccharide motif on the left-wing of the triterpene core and C23-aldehyde in eliciting adjuvant activity of QS-21-derived vaccine adjuvants is a debatable topic. We synthesized novel QS-21 analogues having a disaccharide sugar motif attached to the left side of the triterpene core with varied acyl chain lengths. Our synthesized compounds demonstrate better adjuvant activity as compared to TQL-1055, which indicates that the left-wing sugar motif is important in eliciting adjuvant activity; moreover, our synthesized compounds VA-204 and VA-205 also demonstrate better adjuvant activity as compared to QS-21. We also synthesized QS-21 analogues in which the C23-aldehyde group was replaced with oxime (VA-207), alcohol (VA-208), and carboxylic acid (VA-209) groups; these compounds showed reduced toxicity while retaining the activity, indicating that C23-aldehyde is not imperative and its conversion leads to reduced toxicity. This strategy can be employed to reduce the toxicity associated with QS saponin natural products.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.